Urologix, Inc. was founded with the core mission of developing and marketing minimally invasive medical products for the treatment of urological disorders, specifically benign prostatic hyperplasia (BPH). The company's flagship product, the Targis System, is a non-surgical, anesthesia-free, catheter-based therapy that utilizes proprietary microwave technology to treat BPH. Urologix aims to provide effective, patient-friendly solutions that can significantly improve the quality of life for men suffering from this common condition.
Notable affiliated people and investors include key figures in the medical device industry who have supported Urologix's innovative approach to BPH treatment. The company has achieved significant milestones, including FDA approval for its Targis System and widespread adoption in urology practices. Urologix's impact is evident in its ability to offer a less invasive alternative to traditional surgical procedures, thereby reducing recovery times and associated risks for patients.
